Zobrazeno 1 - 10
of 185
pro vyhledávání: '"Ji Dong, Jia"'
Autor:
Xu Fan, Pei Lu, Xiang-Hua Cui, Peng Wu, Wei-Ran Lin, Dong Zhang, Shong-Zong Yuan, Bing Liu, Fang-Yan Chen, Hong You, Han-Dong Wei, Fu-Chu He, Ji-Dong Jia, Ying Jiang
Publikováno v:
Stem Cell Research & Therapy, Vol 14, Iss 1, Pp 1-14 (2023)
Abstract Background Kupffer cells (KCs) originate from yolk-sac progenitors before birth. Throughout adulthood, they self-maintain independently from the input of circulating monocytes (MOs) at a steady state and are replenished within 2 weeks after
Externí odkaz:
https://doaj.org/article/4188f17dc0e14543bffc5f2eeb1ede33
Autor:
Ai-Ting Yang, Yong-Ook Kim, Xu-Zhen Yan, Hiroyuki Abe, Misbah Aslam, Kyoung-Sook Park, Xin-Yan Zhao, Ji-Dong Jia, Thomas Klein, Hong You, Detlef Schuppan
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 15, Iss 4, Pp 841-867 (2023)
Background & Aims: Fibroblast activation protein (FAP) is expressed on activated fibroblast. Its role in fibrosis and desmoplasia is controversial, and data on pharmacological FAP inhibition are lacking. We aimed to better define the role of FAP in l
Externí odkaz:
https://doaj.org/article/abf59c39cc024052aa821f143340b668
Autor:
Xue-Ru Yin, Zhi-Hong Liu, Jing Liu, Yuan-Yuan Liu, Li Xie, Li-Bo Tao, Ji-Dong Jia, Fu-Qiang Cui, Gui-Hua Zhuang, Jin-Lin Hou, Li-Min Chen
Publikováno v:
Chinese Medical Journal, Vol 132, Iss 19, Pp 2315-2324 (2019)
Abstract. Background:. Nucleos(t)ide analog (NA) in combination with peginterferon (PegIFN) therapy in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) shows better effectiveness than NA monotherapy in hepatitis B surfac
Externí odkaz:
https://doaj.org/article/62069c187dab4cb39115f8748d94b6ee
Autor:
Che-Rung Liu, Xi Li, Po-lin Chan, Hui Zhuang, Ji-Dong Jia, Xiaochun Wang, Ying-Ru Lo, Nick Walsh
Publikováno v:
International Journal of Infectious Diseases, Vol 80, Iss , Pp 16-27 (2019)
Background and aim: Chronic hepatitis C is a major global health challenge. China has the world’s largest burden of hepatitis C and related liver disease, with several groups having an increased risk of acquiring hepatitis C virus (HCV) infection.
Externí odkaz:
https://doaj.org/article/a2b7cce40e1443f8be61870f7e7cc07c
Autor:
Xiao Fei Tong, Xin Yan Zhao, Ya Meng Sun, Yi Wen Shi, Min Li, Xiao Ning Wu, Jing Jie Zhao, Li Ling Yang, Zheng Zhao Lu, Xiao Juan Ou, Ji Dong Jia, Qian Yi Wang, Hong You
Publikováno v:
Journal of Digestive Diseases. 24:28-38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcd3ddbf984935da1620ef89b52a3899
https://doi.org/10.1111/1751-2980.13163
https://doi.org/10.1111/1751-2980.13163
Autor:
Ji-Dong Jia, Wen Xie, Hui-Guo Ding, Hua Mao, Hui Guo, Yonggang Li, Xiaojin Wang, Jie-Fei Wang, Wei Lu, Cheng-Zhong Li, Yimin Mao, Gui-Qiang Wang, Yue-qiu Gao, Bangmao Wang, Qin Zhang, Yan Ge, Vincent Wai-Sun Wong
Publikováno v:
Annals of Hepatology, Vol 16, Iss 1, Pp 123-132 (2017)
Introduction and aim: Hyponatremia is common in patients with decompensated cirrhosis and is associated with increased mortality. Tolvaptan, a vasopressor V2 receptor antagonist, can increase free water excretion, but its efficacy and safety in cirrh
Externí odkaz:
https://doaj.org/article/f319569c90ea4f349fc3fcc8b7dcebad
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Frontiers in Genetics, Vol 10 (2019)
IntroductionCirrhosis is one of the most important risk factors for development of hepatocellular carcinoma (HCC). Recent studies have shown that removal or well control of the underlying cause could reduce but not eliminate the risk of HCC. Therefor
Externí odkaz:
https://doaj.org/article/f7b29e8b289640a9b7850545bc396160
Autor:
Xiao-Fei, Tong, Qian-Yi, Wang, Xin-Yan, Zhao, Ya-Meng, Sun, Xiao-Ning, Wu, Li-Ling, Yang, Zheng-Zhao, Lu, Xiao-Juan, Ou, Ji-Dong, Jia, Hong, You
Publikováno v:
Acta Pharmacol Sin
Nonalcoholic steatohepatitis (NASH) is increasingly recognized as a serious disease that can lead to cirrhosis, hepatocellular carcinoma (HCC), and death. However, there is no effective drug to thwart the progression of the disease. Development of ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aedc1d1d47bbea2a0d387511074195b
https://doi.org/10.1038/s41401-022-00874-x
https://doi.org/10.1038/s41401-022-00874-x
Autor:
Gregory Cheng, Rino Alvani Gani, Ji Dong Jia, Diana A. Payawal, Guo Feng Chen, Khin Maung Win, Simone I. Strasser, Zhen Wen Liu, Hasmik Ghazinian, Saeed Hamid, Tony Mok, Tanwandee Tawesak, Jer Ming Chang, Ann-Lii Cheng, Shiv Kumar Sarin, Jin Lin Hou, Rosmawaiti Mohamed, Pierce K. H. Chow, Grace Lai-Hung Wong, Masashi Mizokami, Patrick Lau, Woon Leung Ng, George Lau, Teerha Piratvisuth, Oidov Baatarkhuu, A. Kadir Dokmeci, Ming-Lung Yu, Alexander J. Thompson, Masao Omata, Joong-Won Park
Publikováno v:
Hepatology International
Background & Aim Hepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clini
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae2c6fb7be712487ce1e61ca1628353b
https://doi.org/10.1007/s12072-021-10239-x
https://doi.org/10.1007/s12072-021-10239-x